UNITY Biotechnology to Participate in Upcoming Investor Conferences
UNITY Biotechnology (NASDAQ: UBX), a company focused on developing therapeutics for age-related diseases, has announced its participation in two upcoming investor conferences. The company will provide corporate updates and engage in one-on-one meetings at these events:
1. H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024, at 7:00 a.m. ET (virtual presentation)
2. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 7:00 a.m. ET in New York, NY
Live webcasts of both presentations will be available through UNITY's website, with archived replays accessible for 90 days after the events. These conferences provide UNITY with opportunities to showcase its progress in developing treatments to slow, halt, or reverse diseases of aging.
UNITY Biotechnology (NASDAQ: UBX), un'azienda focalizzata sullo sviluppo di terapie per malattie legate all'invecchiamento, ha annunciato la sua partecipazione a due prossimi eventi di investimento. L'azienda fornirà aggiornamenti aziendali e parteciperà a incontri individuali durante questi eventi:
1. Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright il 15 agosto 2024, alle 7:00 a.m. ET (presentazione virtuale)
2. 26° Conferenza Annuale Globale sugli Investimenti H.C. Wainwright il 9 settembre 2024, alle 7:00 a.m. ET a New York, NY
I webcast live di entrambe le presentazioni saranno disponibili sul sito web di UNITY, con repliche archiviate accessibili per 90 giorni dopo gli eventi. Queste conferenze offrono a UNITY opportunità per mostrare i suoi progressi nello sviluppo di trattamenti per rallentare, fermare o invertire le malattie legate all'invecchiamento.
UNITY Biotechnology (NASDAQ: UBX), una empresa centrada en el desarrollo de terapias para enfermedades relacionadas con la edad, ha anunciado su participación en dos próximas conferencias de inversores. La empresa proporcionará actualizaciones corporativas y participará en reuniones uno a uno en estos eventos:
1. Conferencia Virtual Anual de Oftalmología H.C. Wainwright el 15 de agosto de 2024, a las 7:00 a.m. ET (presentación virtual)
2. 26ª Conferencia Anual Global de Inversiones H.C. Wainwright el 9 de septiembre de 2024, a las 7:00 a.m. ET en Nueva York, NY
Las transmisiones en vivo de ambas presentaciones estarán disponibles a través del sitio web de UNITY, con repeticiones archivadas accesibles durante 90 días después de los eventos. Estas conferencias brindan a UNITY oportunidades para mostrar su progreso en el desarrollo de tratamientos para ralentizar, detener o revertir las enfermedades del envejecimiento.
UNITY Biotechnology (NASDAQ: UBX)는 노화 관련 질병 치료 개발에 집중하는 회사로, 다가오는 두 개의 투자자 회의에 참여한다고 발표했습니다. 회사는 이 행사에서 기업 업데이트를 제공하고 일대일 미팅에 참여할 예정입니다:
1. H.C. Wainwright 제4회 연례 안과 가상 회의가 2024년 8월 15일 오전 7시 ET에 열립니다 (가상 발표)
2. H.C. Wainwright 제26회 연례 글로벌 투자 회의가 2024년 9월 9일 오전 7시 ET에 뉴욕, NY에서 열립니다
두 발표의 라이브 웹캐스트는 UNITY의 웹사이트를 통해 제공되며, 이벤트 후 90일 동안 아카이브 재생이 가능합니다. 이러한 회의는 UNITY가 노화 질병을 늦추거나 중단하거나 되돌릴 수 있는 치료 개발의 진전을 보여줄 수 있는 기회를 제공합니다.
UNITY Biotechnology (NASDAQ: UBX), une entreprise axée sur le développement de thérapeutiques pour les maladies liées à l'âge, a annoncé sa participation à deux prochaines conférences d'investisseurs. L'entreprise fournira des mises à jour corporatives et participera à des réunions individuelles lors de ces événements :
1. 4ème Conférence Virtuelle Annuelle d'Oftalmologie H.C. Wainwright le 15 août 2024, à 7h00 ET (présentation virtuelle)
2. 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright le 9 septembre 2024, à 7h00 ET à New York, NY
Des webinaires en direct des deux présentations seront disponibles sur le site Web de UNITY, avec des rediffusions archivées accessibles pendant 90 jours après les événements. Ces conférences offrent à UNITY des occasions de montrer ses progrès dans le développement de traitements visant à ralentir, stopper ou inverser les maladies liées à l'âge.
UNITY Biotechnology (NASDAQ: UBX), ein Unternehmen, das sich auf die Entwicklung von Therapien für altersbedingte Krankheiten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird bei diesen Veranstaltungen Unternehmensupdates bereitstellen und an Einzelgesprächen teilnehmen:
1. H.C. Wainwright 4. jährliche virtuelle Augenheilkunde-Konferenz am 15. August 2024 um 7:00 Uhr ET (virtuelle Präsentation)
2. 26. jährliche globale Investorenkonferenz von H.C. Wainwright am 9. September 2024 um 7:00 Uhr ET in New York, NY
Die Live-Webcasts beider Präsentationen sind über die Website von UNITY verfügbar, mit archivierten Wiederholungen, die 90 Tage nach den Veranstaltungen zugänglich sind. Diese Konferenzen bieten UNITY die Möglichkeit, Fortschritte bei der Entwicklung von Behandlungen zu präsentieren, die dazu dienen, altersbedingte Krankheiten zu verlangsamen, zu stoppen oder umzukehren.
- None.
- None.
SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one meetings at the following investor conferences.
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Presentation Date and Time: Thursday, August 15, 2024 at 7:00 a.m. ET
Location: Virtual
Webcast Link: Webcast
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Date and Time: Monday, September 9, 2024 at 7:00 a.m. ET
Location: New York, NY
Webcast Link: Webcast
The live webcasts of the presentations will be accessible through the “Investors & Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.” Archived replays will be available for 90 days following the events.
About UBX1325
UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting Bcl-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with retinal disease.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
When is UNITY Biotechnology (UBX) presenting at the H.C. Wainwright Ophthalmology Virtual Conference?
Where can investors access the webcast for UNITY Biotechnology's (UBX) presentations?
How long will the archived replays of UNITY Biotechnology's (UBX) conference presentations be available?
What is the focus of UNITY Biotechnology's (UBX) therapeutic development?
